BioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017
(Thomson Reuters ONE) -
BioNTech AG /
BioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MAINZ, Germany, Dec. 22, 2016 (GLOBE NEWSWIRE) -- BioNTech AG, a fully
integrated biotechnology company developing truly individualized cancer
immunotherapies, today announced that Sean Marett, COO of BioNTech, will be
presenting at 35th Annual J.P. Morgan Healthcare Conference that is being held
in San Francisco, CA, January 9 - 12, 2017. The presentation is scheduled for
Wednesday, January 11th at 9:30 AM Pacific Standard Time. Mr. Marett will
provide an overview of the company's strategy and its most recent substantial
progress, including an update of its clinical pipeline, an overview of its
strategic collaborations, a summary of its two most recent Nature publications
related to its individualized mRNA cancer vaccines and the establishment of a
second mRNA production facility at the Company's headquarters in Germany.
The J.P. Morgan Healthcare Conference brings together corporate leaders,
financial sponsors and institutional investors to explore market and sector
trends.
About BioNTech AG
BioNTech AG is an immunotherapy leader with bench-to-market capabilities,
developing truly personalized, well-tolerated and potent treatments for cancer
and other diseases. Established by clinicians and scientists the Group is
pioneering disruptive technologies ranging from individualized mRNA based
medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based
products and novel bispecific antibody immunomodulators. BioNTech's clinical
programs are supported by an in-house molecular diagnostics unit whose products
include MammaTyper® a molecular in-vitro diagnostic kit, marketed under CE and
IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is
privately held and shareholders include the MIG Fonds, Salvia, and the
Strüngmann Family Office, with the Strüngmann Family Office as the majority
shareholder.
Information about BioNTech is available at www.biontech.com.
For meeting requests or further information, please contact:
BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273
Email: Regina.Jehle(at)biontech.de
Investors:
Stephanie Carrington
ICR, Inc.
646-277-1282
Stephanie.Carrington(at)icrinc.com
Media:
James Heins
ICR, Inc.
203-682-8251
James.Heins(at)icrinc.com
European Media & Investors:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BioNTech AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.12.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 514485
Anzahl Zeichen: 3494
contact information:
Town:
Mainz
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
BioNTech AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
